Skip to content

Tesamorelin from bench to bedside FDA approval

January 5, 2026 · 12 min

Show notes

This episode is designed for listeners interested in clinical research, peptide science, endocrinology, and translational medicine, offering an evidence-based perspective without speculation or medical advice.

Topics include:

  • Tesamorelin peptide mechanism of action
  • Preclinical and animal studies
  • Phase II and Phase III clinical trial data
  • FDA approval and HIV-associated lipodystrophy
  • Growth hormone, IGF-1, and metabolic effects
  • Safety, limitations, and ongoing research

All episodes of Today’s discussion

Settings

Display

Language

Decides which stations you see first on the home page.

History

Recently played stations and episodes and your latest searches are only stored in this browser.

Notifications

A short notice when a podcast you follow has a new episode. Turn off single podcasts with the bell on their page.

Account

Save favorites – in the app and on the website.

Keyboard shortcuts

/
Open search
Space
Play or pause
← →
In the player: back 15 s, forward 30 s (episodes) · in a row: next tile
↑ ↓
In a row: target within the tile
Home / End
In a row: first or last tile
Esc
Close window or menu
?
This overview
Now playing

Go to station page

Play next

    Add episodes with “Play next” – they play after the current episode.